
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics Inc. is positioned for significant revenue growth, with projections estimating revenues approaching $560 million by 2028, primarily driven by advancements in the sickle cell disease market where few treatment options exist. Clinical data has demonstrated that the company’s lead candidate, pociredir, effectively increases fetal hemoglobin levels and improves key health metrics, such as a 44% response rate in patients achieving notable increases in total hemoglobin, which is linked to better survival outcomes. Furthermore, improvements in red blood cell health, including substantial reductions in biomarkers of hemolysis, support the therapeutic effectiveness of their treatments, enhancing the company’s prospects in the biopharmaceutical space.
Bears say
Fulcrum Therapeutics faces a negative outlook largely due to concerns over its weaker SCPC profile, which raises doubts about the potential for regulatory approval based solely on hemoglobin correction. The company has indicated that the early patients in the 20mg cohort exhibited lower baseline HbF levels, further complicating the prospects for successful clinical outcomes and commercialization. Additionally, any negative developments regarding trial readouts or regulatory submissions could significantly hinder Fulcrum's market potential and competitive positioning.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares